Pfizer/Aventis Exubera NDA Delayed Until 2002; FDA May Require More Data
Executive Summary
Pfizer/Aventis' Exubera inhaled insulin NDA is not expected to be filed until the second half of 2002 if FDA requires additional data, according to development partner Inhale Therapeutic Systems.
You may also be interested in...
Pfizer Exubera Launch May Demonstrate Impact Of Revised DTC Ad Policy
Launch of Pfizer/Sanofi-Aventis' inhaled insulin Exubera could demonstrate the impact of Pfizer's new direct-to-consumer advertising guidelines
Pfizer Exubera Launch May Demonstrate Impact Of Revised DTC Ad Policy
Launch of Pfizer/Sanofi-Aventis' inhaled insulin Exubera could demonstrate the impact of Pfizer's new direct-to-consumer advertising guidelines
Pfizer/Aventis File For Exubera In Europe; No Timeline Yet On U.S. NDA
Pfizer and Aventis have filed for European regulatory approval of the inhaled insulin Exubera